Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lactobacillus rhamnosus ccfm1130 and its application in the treatment of gout

A CCFM1130, Lactobacillus rhamnosus technology, applied in the field of microorganisms, can solve problems such as undiscovered, and achieve the effects of promoting expression, reducing serum uric acid levels, and reducing gout

Active Publication Date: 2022-07-05
JIANGNAN UNIV
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The excretion of uric acid in the human body is mainly through the excretion of the kidneys and intestines. As a uric acid transporter, ABCG2 plays an important role in the intestinal excretion of uric acid. The expression of intestinal ABCG2 is considered to be a new target for the treatment of hyperuricemia and gout. point, but currently no drugs targeting intestinal ABCG2 have been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactobacillus rhamnosus ccfm1130 and its application in the treatment of gout
  • Lactobacillus rhamnosus ccfm1130 and its application in the treatment of gout
  • Lactobacillus rhamnosus ccfm1130 and its application in the treatment of gout

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 Screening of Lactobacillus rhamnosus CCFM1130

[0050] (1) Isolation and screening of Lactobacillus

[0051] (1) Take 1g of fresh feces from healthy adults. After gradient dilution, it was coated on LBS medium supplemented with 1% nystatin, and cultured in a constant temperature incubator at 37°C for 48h.

[0052] (2) After culturing, according to the color, size, edge shape, etc. of the colony, use the inoculation loop to pick the colony for streak purification.

[0053] (3) The obtained colonies were subjected to Gram staining and catalase analysis.

[0054] (4) Retain Gram-positive bacilli and catalase-negative bacteria.

[0055] (2) Molecular biological identification of Lactobacillus

[0056] (1) Single bacterial genome extraction

[0057] (A) the lactobacillus obtained by step (1) is cultivated overnight;

[0058] (B) get 1mL of bacterial suspension cultured overnight in a 1.5mL centrifuge tube, centrifuge at 10000r / min for 2min, discard the supernat...

Embodiment 2

[0074] Example 2: Tolerance test of Lactobacillus rhamnosus CCFM1130 to simulated gastrointestinal fluid

[0075] The cryopreserved Lactobacillus rhamnosus CCFM1130 was inoculated into MRS medium, cultured at 37°C for 14 hours, and then subcultured with MRS medium for 2 to 3 times.

[0076] Take 3 mL of Lactobacillus rhamnosus CCFM1130 culture solution by centrifugation at 8000 × g for 2 min to collect bacterial cells, mix with 3 mL of pH 3.0 artificial simulated gastric juice (containing 3 g / L pepsin, pH=3.0 normal saline), and incubate at 37 °C Culture, samples were taken at 0h and 2h respectively, and the plate colonies were counted with MRS agar medium for pouring and culture, and the number of viable bacteria was determined and the survival rate was calculated.

[0077] Take 3 mL of Lactobacillus rhamnosus CCFM1130 culture solution by centrifugation at 8000 × g for 2 min to collect the bacterial cells, add 3 mL of pH8.0 artificial simulated intestinal fluid (physiological...

Embodiment 3

[0081] Example 3: Lactobacillus rhamnosus CCFM1130 has no toxic and side effects on KunMing mice

[0082] The Lactobacillus rhamnosus CCFM1130 bacteria were resuspended in 100g / L skim milk solution, and the concentration was 4.0×10. 9 CFU / mL bacterial suspension. Twelve healthy male KunMing mice weighing about 24-32 g were selected and divided into CCFM1130 group and control group after one week of acclimatization. The CCFM1130 group was given 0.3 mL of this concentration of bacterial suspension by gavage once a day, and the control group was given the same volume of 100 g / L skim milk solution without Lactobacillus rhamnosus CCFM1130 by gavage for one week, and the death and body weight were recorded.

[0083] The results of these tests are listed in Table 2. The results showed that the feeding concentration was 1 × 10 9 CFU / Lactobacillus rhamnosus CCFM1130 did not significantly affect the mice, and there was no significant change in body weight and no death phenomenon. Th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses Lactobacillus rhamnosus CCFM1130 and its application for relieving and treating gout, and belongs to the technical field of microorganisms. The Lactobacillus rhamnosus CCFM1130 of the present invention can reduce the level of serum uric acid in mice with hyperuricemia, inhibit the activity of xanthine oxidase (XOD) in serum and liver, and reduce the occurrence of hyperuricemia and gout; Down-regulates serum total triglyceride (TG), down-regulates serum total cholesterol (TC) level and inhibits serum alkaline phosphatase (ALP) activity; and promotes the expression of ileal uric acid transporter ABCG2. The Lactobacillus rhamnosus CCFM1130 of the invention can tolerate the gastrointestinal tract environment, can be used to prepare functional bacterial agents, foods and medicines that can be ingested in the gastrointestinal tract for relieving hyperuricemia and gout, and has wide application prospects.

Description

technical field [0001] The invention relates to Lactobacillus rhamnosus CCFM1130 and its application for relieving and treating gout, and belongs to the technical field of microorganisms. Background technique [0002] Hyperuricemia (Hyperuricemia, HUA) refers to a disease in which the level of uric acid in the blood exceeds the normal value. In recent years, with the improvement of living standards, the incidence of hyperuricemia is also increasing, and patients with hyperuricemia in my country account for about 13.3% of the total population. Urate stones caused by long-term hyperuricemia can further induce gout. At the same time, hyperuricemia is considered to be a risk factor for cardiovascular and cerebrovascular diseases, chronic kidney disease, and atherosclerosis, which seriously endangers human health. Therefore, the treatment of hyperuricemia has attracted great attention. At present, the main drugs for the treatment of hyperuricemia are allopurinol (xanthine oxida...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A61K35/747A61P19/06A23L33/135C12R1/225
CPCC12N1/20A61K35/747A61P19/06A23L33/135A23V2002/00A23V2400/175A23V2200/30A23V2200/328A23V2200/3262Y02A50/30
Inventor 王刚倪彩新王琳琳翟齐啸陆文伟崔树茂杨波毛丙永唐鑫赵建新张灏陈卫
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com